Surbhi Sidana
Associate Director for Clinical Research, BMT/Cell Therapy, Stanford University · Stanford Health Care
Credentials: · · · · · · ·
History
- Present
- Present
- Present
2012–2015- 2007–2011
Doctor of Medicine
Research
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2022 · 1,060 citations
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine · 2023 · 713 citations
Nature Medicine · 2021 · 534 citations
43 papers
- DH
38 papers
36 papers
32 papers
31 papers
31 papers
- YL
31 papers
30 papers
Clinical trials
- 2025–2029
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Principal investigator · Recruiting · Phase 2
Stanford University
- 2021–2022
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Principal investigator · Completed
Stanford University
- 2020–2022
Principal investigator · Completed · Phase 2
Surbhi Sidana, MD
- 2025–2042
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Site PI · Recruiting · Phase 1
Kelonia Therapeutics, Inc.